Who are fordadistrogene movaparvovec's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): rAd-p53 gene, p53 gene with surgery, voretigene neparvovec-rzyl, chemotherapy plus p53, p53 with chemotherapy, p53 gene therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fordadistrogene-movaparvovec.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

fordadistrogene movaparvovec — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

fordadistrogene movaparvovec (fordadistrogene-movaparvovec) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy; In vivo gene delivery. Area: Rare Disease.

discontinued Gene therapy; In vivo gene delivery Dystrophin gene (DMD); AAV9 receptor (AAVR) Rare Disease Gene therapy Live · refreshed every 30 min

Target snapshot

fordadistrogene movaparvovec (fordadistrogene-movaparvovec) — Pfizer Inc.. Fordadistrogene movaparvovec delivers a functional dystrophin gene via AAV9 vector to restore muscle protein expression in Duchenne muscular dystrophy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
fordadistrogene movaparvovec TARGET	fordadistrogene-movaparvovec	Pfizer Inc.	discontinued	Gene therapy; In vivo gene delivery	Dystrophin gene (DMD); AAV9 receptor (AAVR)
rAd-p53 gene	rAd-p53 gene	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy; oncolytic virus	p53 tumor suppressor gene
p53 gene with surgery	p53 gene with surgery	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy (p53 tumor suppressor)	p53 (tumor protein p53)
voretigene neparvovec-rzyl	voretigene neparvovec-rzyl	Spark Therapeutics, Inc.	marketed	Gene therapy	RPE65 gene
chemotherapy plus p53	chemotherapy plus p53	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Combination chemotherapy with p53 gene therapy	p53 tumor suppressor protein
p53 with chemotherapy	p53 with chemotherapy	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy; recombinant adenovirus vector	p53 (tumor suppressor protein)
p53 gene therapy	p53 gene therapy	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy	p53 (tumor suppressor protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy; In vivo gene delivery class)

Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fordadistrogene movaparvovec — Competitive Intelligence Brief. https://druglandscape.com/ci/fordadistrogene-movaparvovec. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab